The DOI matches its Crossref record, with a small difference in title or year; 119 of the 119 references it cites were found in a registry or an index.
Metabolic syndrome and hepatocellular carcinoma: Two growing epidemics with a potential link
Open accessAbstract
Hepatocellular carcinoma (HCC) is the most rapidly increasing cause of cancer death in the United States. Although many risk factors for HCC are well defined, including hepatitis B virus (HBV), hepatitis C virus (HCV), and alcohol, most series have indicated that 5% to 30% of patients with HCC lack a readily identifiable risk factor for their cancer. The majority of “cryptogenic” HCC in the United States is attributed to nonalcoholic fatty liver disease (NAFLD), a hepatic manifestation of the metabolic syndrome. The metabolic syndrome is a constellation of problems that includes insulin resistance, obesity, hypertension, and hyperlipidemia. Increasingly, components of the metabolic syndrome are being linked to various forms of cancer with respect to both increased risk of disease and worsened outcome. In this review, the authors focused on the relation between metabolic syndrome and HCC. They investigated the increased risks of HCC among individuals with features of metabolic syndrome, potentially worsened cancer outcomes in these patients, possible pathogenic mechanisms to explain these relations, and treatment options for those with NAFLD and its progressive counterpart, nonalcoholic steatohepatitis. It is predicted that metabolic syndrome will lead to large increases in the incidence of HCC over the next decades. A better understanding of the relation between these 2 diseases ultimately should lead to improved screening and treatment options for patients with HCC. Cancer 2009. © 2009 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“non-alcoholic fatty liver disease (NAFLD) is predicted to become the leading cause of HCC in the 21st century as a secondary consequence of the obesity pandemic (Siegel and Zhu, 2009).”
From Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis (2016) · cites this paper as Siegel and Zhu, 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,404
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Research works printed but not linked: 1
- 10.1111/j.1572-0241.2005.41583.x · DOI
Cited by
Sorted by citations
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
Starley, B. Q., Calcagno, C. J., & Harrison, S. A. (2010) · Hepatology · doi:10.1002/hep.23594 · Cited by 1,349
Non-alcoholic fatty liver disease: An expanded review
Benedict, M., & Zhang, X. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i16.715 · Cited by 788
Welzel, T. M., Graubard, B. I., Zeuzem, S., El‐Serag, H. B., Davila, J. A., & McGlynn, K. A. (2011) · Hepatology · doi:10.1002/hep.24397 · Cited by 539
Ertle, J., Dechêne, A., Sowa, J., Penndorf, V., Herzer, K., Kaiser, G. M., Schlaak, J., Gerken, G., Syn, W., & Canbay, A. E. (2010) · International Journal of Cancer · doi:10.1002/ijc.25797 · Cited by 526
Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis
Kettner, N. M., Voicu, H., Finegold, M. J., Coarfa, C., Sreekumar, A., Putluri, N., Katchy, C. A., Lee, C., Moore, D. D., & Fu, L. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.007 · Cited by 508
“Among these diseases, non-alcoholic fatty liver disease (NAFLD) is predicted to become the leading cause of HCC in the 21st century as a secondary consequence of the obesity pandemic (Siegel and Zhu, 2009).”
Background
Metadata
- Authors
- Siegel, A. B., & Zhu, A. X.
- Affiliations
- Columbia University (US)
- Harvard University (US)
- Corresponding author
- Siegel, Abby B.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-10-15
- Volume
- 115
- Issue
- 24
- Pages
- 5651-5661
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- PMC
- PMC3397779
- OpenAlex
- W1995501999
- Cited by
- 399
- References
- 118
- Citations by year
- 2026: 3 · 2025: 15 · 2024: 19 · 2023: 12 · 2022: 19 · 2021: 22 · 2020: 19 · 2019: 19 · 2018: 22 · 2017: 25 · 2016: 15 · 2015: 27 · 2014: 29 · 2013: 45 · 2012: 34
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Center for Research Resources (K12 RR024157-03, KL2RR024157)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- metabolic syndrome, hepatocellular carcinoma, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, insulin resistance, obesity, hypertension, hyperlipidemia, cancer risk factors, oncological outcomes, pathophysiological mechanisms, HCC screening, HCC treatment
- MeSH terms
- Fatty Liver, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Obesity, Risk Factors, United States, Incidence, Survival Rate, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
